FIRECREST Customer Support

The FDA’s new support of a single study approach has drawn much discussion, raising questions as to whether conducting just one confirmatory study is a risky position for sponsors to take. In this blog, Andrew Garrett,...

As ART has transformed the outlook for people aging with HIV, it must also transform our approach to healthcare as this population develops comorbidities. Explore the next generation of therapies and care models needed t...

We’re gearing up for ISPOR 2026 - what HEOR or real world evidence challenges are you focused on this year? Stop by Booth \#1017 at #ISPORAnnual to exchange ideas and explore how ICON can support your evidence strategy...

AI is rapidly reshaping how life sciences companies generate insight, accelerate development, and scale smarter decision-making. This BioSpectrum Asia Asia piece highlights the AI tools leading organisations are alread...

Risk-based monitoring isn’t about doing less. It’s about doing the right work, in the right place, at the right time – but that looks different for every study. As RBQM adoption accelerates, sponsors are moving beyond b...

A key challenge in dermatology has been the lack of a simple, reliable, and standardized tool to measure nail psoriasis severity - particularly in clinical trials. A newly published study co-authored by ICON introduces t...

Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our free monthly publication b...

Medical writing is evolving rapidly. From AI-supported workflows and patient-focused communication to increasingly complex global regulations, the role of medical writers is becoming more strategic than ever before. Wh...

The real-world success of monoclonal antibodies (mAbs) to treat neurologic conditions relies heavily on strict adherence to clinical operational protocols, rather than just on the strength of their biological mechanisms ...

Biosimilar formulation development is becoming more complex as patient-centric design, high concentration products and evolving regulatory expectations converge. In a recent PharmTech Q&A, ICON’s Kim Salgado and Venkat ...

Reaching the right patients starts with the right sites. Connect with us at ASCO, booth \#35093, to learn how ICON expands site reach by activating patient dense regions and engaging high potential sites, including Acce...

Meet the ICON team at booth \#26 during DIA China, taking place 13–16 May in Shanghai. ICON will be attending the conference and looks forward to connecting with peers to discuss perspectives on clinical development and...